Hypoxia is associated with increased metastatic potential and poor prognosis in solid tumors. In this study, we demonstrated in the murine 5T33MM model that multiple myeloma (MM) cells localize in an extensively hypoxic niche compared to the naive bone marrow (BM). Next, we investigated whether hypoxia could be used as a treatment target for MM by evaluating the effects of a new hypoxia-activated prodrug TH-302 in vitro and in vivo. In severely hypoxic conditions, induces Go/G1 cell cycle arrest by down-regulating cyclinD1/2/3, CDK4/6, p21 cip-1 , p27
Introduction
Multiple myeloma (MM) is an incurable clonal B cell malignancy characterized by the accumulation of neoplastic plasma cells in the bone marrow (BM). 1 Studies have shown that the intimate reciprocal relationship between tumor cells and the cellular and noncellular microenvironment plays a pivotal role in MM growth and survival. 2, 3 Hypoxia, one of the important microenvironmental factors, is well known to be highly associated with increased angiogenesis and metastatic potential as well as poor prognosis in solid tumors. More recently, hypoxia has been demonstrated to be crucial for normal marrow hematopoiesis [4] [5] [6] . However, the role of hypoxia in the etiology, pathogenesis, and possible treatment of hematological malignancies, such as MM, is still unknown.
Given very low oxygen levels, as found in tumors, are rarely observed in normal tissues, the presence of hypoxic tumor cells is therefore regarded not only as an adverse prognostic factor but also as a potential target for tumor-specific treatment. Currently, a number of hypoxia-targeted 
Materials and Methods (see supplementary material)
All experiments were approved by the Ethical Committee for Animal Experiments at Vrije Universiteit Brussels.
Results and Discussion
Despite major therapeutic advances, MM still remains incurable. 1 Compelling evidence suggests that the BM microenvironment favors MM progression by promoting MM cell growth and drug resistance. In solid tumors, hypoxia is one of the microenvironmental factors that drives tumor progression and treatment resistance. MM develops in a specialized BM microenvironment, which has been shown to be low in oxygen tension, however, our knowledge in this field is still in its infancy and many details are unkown. [15] [16] [17] [18] In contrast to solid tumors and other tissues or organs, the inaccessibility of the BM to direct noninvasive oxygen measurements is a major hurdle for formal experimental investigation. Moreover, the invasive needle oxygen electrode techniques for Figure 4) . In addition, we demonstrated that the production of HIF1α, the central regulator of the hypoxic response, 23 is decreased with the treatment of TH-302. The expression of HIF1α in a hypoxic condition was reduced following exposure to TH-302 ( Figure 1F , similar results were also found in 5T33vt, LP-1, Karpas-707 cells, see Supplementary Figure 5) , accordingly, the secretion of VEGFa which is a downstream target gene of HIF1α was also significantly decreased ( Figure 1G ). (Figure 2 ) .
By employing a set of defined gas mixtures (0%, 1%, 1.25%, 1.5%, 2%, 3%, 20% O 2 ) for drug treatment of the MM cells, we evaluated the oxygen concentration dependent activation of TH-302.
Our results suggest that the threshold of activating prodrug TH-302 is lower than 1.5% O 2 (Supplementary Figure 6) . 2-nitroimidazole (the oxygen concentration sensing trigger for both pimonidazole and TH-302) has been shown to become activated in cells whose oxygen concentration is < 10 mmHg pO 2 , 24, 25 it is reasonable to accept that the cytotoxic effect of TH-302 is tightly associated with the hypoxic nature of MM cells in the BM. In addition, the data from TH-302 treated naive mice show no significant toxicity in body weight, hemoglobin (HGB), red blood cell count (RBC), white blood cell count (WBC), hematocrit (HCT) and MVD, compared to the vehicle-treated naive mice, further indicating the specific hypoxia-activated effect of TH-302 and the limited hypoxia in the normal BM (Supplementary Figure 7) . 
